JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 29, 2025, titled "Press Release".
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals has agreed to buy a 46.39% controlling stake in JB Chemicals & Pharmaceuticals from private equity firm KKR at INR 1,600 per share, valuing the transaction at INR 11,917 crores. Total equity valuation of JB Pharma is INR 25,689 crores on a fully diluted basis. A mandatory open offer will follow for an additional 26% of shares from public shareholders at INR 1,639.18 per share, plus up to 2.80% from employees at the same price as KKR. After the acquisition, Torrent and JB Pharma will merge, with JB Pharma shareholders receiving 51 shares of Torrent for every 100 shares they hold. The deal aims to combine Torrent's chronic therapy strength with JB Pharma's growing India franchise and CDMO capabilities, subject to SEBI, CCI, NCLT and stock exchange approvals.
JB Pharma shareholders stand to receive a meaningful exit opportunity at a premium via the open offer, while also becoming shareholders in the larger merged Torrent entity. The merger would create a stronger combined pharma player, but the share swap ratio (51:100) may dilute JB Pharma shareholders' proportional ownership in the combined company.